DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF) gapped up before the market opened on Friday . The stock had previously closed at $74.25, but opened at $81.90. DiaSorin shares last traded at $80.25, with a volume of 3,100 shares trading hands.

Analyst Upgrades and Downgrades

DSRLF has been the subject of a number of recent research reports. Piper Sandler started coverage on shares of DiaSorin in a report on Thursday, June 11th. They issued a “neutral” rating for the company. Zacks Research raised shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th. BNP Paribas Exane cut shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Finally, Deutsche Bank Aktiengesellschaft cut DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, DiaSorin has a consensus rating of “Hold”.

DiaSorin Trading Down 4.6%

The stock’s 50-day simple moving average is $74.70 and its 200-day simple moving average is $76.22.

About DiaSorin

DiaSorin S.p.A. is an Italy?based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over?the?counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.